Gantenerumab fails; time for Roche to cut its Alzheimer's losses?
This article was originally published in Scrip
Executive Summary
Roche is dropping a Phase III trial of the anti-amyloid gantenerumab in prodromal Alzheimer's disease patients. The decision calls into question not only the future of this drug, but also that of other disease modifying anti-amyloids, including Roche's crenezumab.
You may also be interested in...
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
EU Pilots New 'Stepwise' Approach To Pediatric Investigation Plans
New EU guidance has been published to help the European Medicines Agency and drug developers agree on the conduct of pediatric investigation plans (PIPs) when crucial information is not yet available.
UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.